Avenge Bio's AVB-001 Granted FDA Orphan Drug Designation for Mesothelioma Treatment

Avenge Bio, Inc., a leading biotech firm specializing in oncology, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AVB-001. This designation recognizes AVB-001 as a promising treatment for patients suffering from mesothelioma. Avenge Bio’s clinical-stage development of AVB-001 brings hope to those affected by this challenging disease.

Publish Date: 15-06-2023 Source: Avenge Bio, Inc.

Mesothelioma is a type of cancer that is primarily attributed to asbestos exposure. It usually affects the lining of the lungs or the abdomen. Following a diagnosis, the average life expectancy ranges from 18 to 31 months; however, advancements in treatment options offer the potential for improved prognosis. Chest pain, general fatigue, and shortness of breath are all possible symptoms. Based on the tumour’s location, there are four main types of mesothelioma. Mesothelioma tumors are made up of various cell types. The three most common types of mesothelioma cells are epithelioid, sarcomatoid, and biphasic. About 75% of all mesothelioma cases are attributed to pleural mesothelioma, making it the most prevalent type.

Around 3,000 people are estimated to be diagnosed with mesothelioma in the United States annually. Globally, around 30,870 individuals were diagnosed with mesothelioma in the year 2020.

However, the current Mesothelioma treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (MesoPher, OT-101, Tazemetostat, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Mesothelioma treatment. The key companies in the advanced development stage are Amphera BV, Oncotelic Inc., Epizyme Inc., etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Mesothelioma to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2021 to 2032.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.